科研之友
微信
新浪微博
Facebook
分享链接
摘要
Significant advances have been made in the last decade toward a better understanding of the disease pathogenesis and the development of novel therapies that target specific subsets of adult acute lymphoblastic leukemia (ALL). Risk-adapted strategies are transforming the disease treatment and prognosis. With current treatment regimens, long-term survival is achieved by approximately 50% of patients with B-cell ALL, 50% to 60% of patients with Philadelphia chromosome-positive ALL, and approximately 80% of patients with Burkitt's leukemia. Genomic profiling in ALL has identified new prognostic markers, new therapeutic targets, and novel ALL subtypes. These may be amenable to future targeted therapies that can further improve outcomes. The early recognition of early precursor T-cell ALL, a distinct pathobiological entity with a poor prognosis, is essential for the development of an effective clinical management strategy. The role of monoclonal antibodies and cytotoxic T-cell therapies continues to be defined. Many of the approaches are currently being evaluated for ALL salvage. Their incorporation into frontline adult ALL therapy, in concomitant or sequential strategies, may increase the cure rates to levels achieved in pediatric ALL and may reduce the need for prolonged intensive and maintenance chemotherapy. Cancer 2015;121:2517-2528. (c) 2015 American Cancer Society. Risk-adapted strategies are transforming the treatment and prognosis of adult acute lymphoblastic leukemia. The role of monoclonal antibodies and cytotoxic T-cell therapies continues to be defined. Their incorporation into frontline adult acute lymphoblastic leukemia therapy may increase the cure rates to levels achieved in pediatric acute lymphoblastic leukemia and may reduce the need for prolonged intensive and maintenance chemotherapy.
- 出版日期2015-8-1
